Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by State of Michigan Retirement System

Posted by Defense World Staff on Apr 12th, 2023

State of Michigan Retirement System lowered its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 1.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 38,360 shares of the company’s stock after selling 500 shares during the quarter. State of Michigan Retirement System’s holdings in Henry Schein were worth $3,064,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. JLB & Associates Inc. boosted its position in Henry Schein by 0.5% during the 4th quarter. JLB & Associates Inc. now owns 87,414 shares of the company’s stock valued at $6,981,000 after purchasing an additional 421 shares during the period. Comerica Bank boosted its position in Henry Schein by 24.4% during the 4th quarter. Comerica Bank now owns 49,044 shares of the company’s stock valued at $3,966,000 after purchasing an additional 9,630 shares during the period. Dupont Capital Management Corp boosted its position in Henry Schein by 73.9% during the 4th quarter. Dupont Capital Management Corp now owns 546 shares of the company’s stock valued at $44,000 after purchasing an additional 232 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its stake in Henry Schein by 41.7% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 14,194 shares of the company’s stock valued at $1,141,000 after acquiring an additional 4,174 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC bought a new stake in Henry Schein during the 4th quarter valued at $321,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Insider Transactions at Henry Schein

In other news, Director Philip A. Laskawy sold 6,405 shares of the business’s stock in a transaction on Friday, March 3rd. The stock was sold at an average price of $78.74, for a total transaction of $504,329.70. Following the sale, the director now directly owns 26,239 shares of the company’s stock, valued at $2,066,058.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Philip A. Laskawy sold 6,405 shares of the business’s stock in a transaction on Friday, March 3rd. The stock was sold at an average price of $78.74, for a total transaction of $504,329.70. Following the sale, the director now directly owns 26,239 shares of the company’s stock, valued at $2,066,058.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kurt P. Kuehn sold 1,909 shares of Henry Schein stock in a transaction on Thursday, March 16th. The shares were sold at an average price of $77.46, for a total value of $147,871.14. Following the transaction, the director now owns 15,675 shares in the company, valued at approximately $1,214,185.50. The disclosure for this sale can be found here. 1.00% of the stock is owned by insiders.

Henry Schein Stock Up 1.6 %

HSIC opened at $85.22 on Wednesday. Henry Schein, Inc. has a one year low of $64.75 and a one year high of $92.68. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.91 and a current ratio of 1.79. The stock’s fifty day moving average is $81.73 and its 200-day moving average is $78.49. The company has a market capitalization of $11.19 billion, a PE ratio of 21.91, a P/E/G ratio of 1.96 and a beta of 0.81.

Henry Schein (NASDAQ:HSIC – Get Rating) last announced its earnings results on Thursday, February 16th. The company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.21 by $0.14. The company had revenue of $3.37 billion for the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a return on equity of 15.79% and a net margin of 4.25%. Henry Schein’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.07 earnings per share. On average, equities analysts predict that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Barrington Research cut their target price on Henry Schein from $99.00 to $92.00 and set an “outperform” rating on the stock in a research note on Friday, February 17th. Morgan Stanley cut their target price on Henry Schein from $70.00 to $69.00 and set an “underweight” rating on the stock in a research note on Tuesday, February 21st. UBS Group lifted their target price on Henry Schein from $75.00 to $82.00 and gave the company a “neutral” rating in a research note on Tuesday, March 7th. Piper Sandler lifted their target price on Henry Schein from $85.00 to $97.00 and gave the company an “overweight” rating in a research note on Monday, February 6th. Finally, StockNews.com raised Henry Schein from a “hold” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $85.89.

About Henry Schein

(Get Rating)

Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins.